echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first TCR-T product for the treatment of liver cancer was approved for clinical use

    The first TCR-T product for the treatment of liver cancer was approved for clinical use

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    On April 20, Guangzhou Xiangxue Pharmaceutical announced that its grandson company Xiangxue Life Sciences TCR-T therapeutic product TAEST1901 injection was approved for clinical use


    In recent years, T cell receptor biopharmaceuticals have received high attention in the industry.


    TAEST1901 injection is the second TCR-T product approved for clinical trials since Xiangxue Life Sciences obtained the IND approval for the first TCR-T product (TAEST16001 injection) in China in March 2019


    TAEST1901 injection is a HLA-A*02:01/AFP specific affinity-enhanced TCR-T therapeutic product, targeting the complex composed of HLA-A*02:01 and AFP antigenic peptides.


    Through systematic preclinical studies, TAEST1901 injection showed good safety


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.